Loading...
Market
What will be IBRANCE's market share in HR+, HER2+ MBC by end of 2025?
2
Resolution / Starting Odds
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Market research reports from firms like IMS Health or EvaluatePharma
Story
Pfizer's IBRANCE Extends PFS by Over 15 Months in HR+, HER2+ MBC: PATINA Study at SABCS 2024
Dec 12, 2024, 01:16 PM
Pfizer Inc. has announced that its drug IBRANCE® (palbociclib), when combined with standard-of-care therapies, significantly extended median progression-free survival (PFS) by over 15 months in the Phase 3 PATINA study for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). The trial demonstrated that the addition of IBRANCE to anti-HER2 therapy (trastuzumab or trastuzumab plus pertuzumab) and endocrine therapy resulted in a median PFS of 44.3 months compared to 29.1 months for patients treated with anti-HER2 therapy and endocrine therapy alone [HR: 0.74 (95% CI, 0.58-0.94); unstratified 1-sided p=0.0074]. This represents the first large Phase 3 study to show the benefit of CDK4/6 inhibition in this patient population. The safety profile of IBRANCE was consistent with previous studies, with no new safety signals identified. The results were presented at the 47th San Antonio Breast Cancer Symposium (SABCS).
View original story
Similar markets
More than 15% • 25%
5% to 10% • 25%
Less than 5% • 25%
10% to 15% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Other • 25%
North America • 25%
Asia • 25%
Europe • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Less than 10% • 25%
More than 15% • 25%
Less than 5% • 25%
10% to 15% • 25%
5% to 10% • 25%
40% to 60% • 25%
More than 60% • 25%
20% to 40% • 25%
Less than 20% • 25%
Other • 25%
Pfizer • 25%
Novartis • 25%
Roche • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
10% to 30% • 25%
Less than 10% • 25%
30% to 50% • 25%
More than 50% • 25%
Increase between 10% and 20% • 25%
No significant increase • 25%
Increase by less than 10% • 25%
Increase by more than 20% • 25%